Journal: Cancer Cell International

Article Title: LncRNA SNHG12 regulates the radiosensitivity of cervical cancer through the miR-148a/CDK1 pathway

doi: 10.1186/s12935-020-01654-5

Figure Lengend Snippet: Effects of SNHG12 knockdown on radiosensitivity in CC cells. SiHa and Hela cells were transfected with si-SNHG12 or si-con. a , b Clonogenic assay was performed to assess the survival fractions of SiHa and Hela cells. c , d The apoptosis of SiHa and Hela cells treated with different doses of radiation (0 Gy and 2 Gy) was determined by flow cytometry. e , f The caspase-3 activity of SiHa and Hela cells treated with different doses of radiation (0 Gy and 2 Gy) was detected by Caspase-3 Activity Assay Kit. g , h Flow cytometry was used to examine the cell cycle distribution in SiHa and Hela cells treated with different doses of radiation (0 Gy and 2 Gy). i , j WB analysis was performed to measure the protein expression of CCND1 in SiHa and Hela cells treated with different doses of radiation (0 Gy and 2 Gy). * P < 0.05

Article Snippet: After blocking with non-fat milk for 2 h, the membranes were incubated with primary antibodies CDK1 (1:500, BA0027-2, Boster, Wuhan, China), CCND1 (1:2000, PB0403, Boster), γ-H2AX (1:1000, AF5836, Beyotime) and β-actin (1:5000, BA2305, Boster) overnight at 4 °C, followed by incubating with secondary antibody (1:10,000, BA1056, Boster) for 1 h. Immunoreactive bands were visualized using enhanced chemiluminescence reagent (Millipore).

Techniques: Transfection, Clonogenic Assay, Flow Cytometry, Activity Assay, Caspase-3 Activity Assay, Expressing

Journal: Cancer Cell International

Article Title: LncRNA SNHG12 regulates the radiosensitivity of cervical cancer through the miR-148a/CDK1 pathway

doi: 10.1186/s12935-020-01654-5

Figure Lengend Snippet: Effects of miR-148a inhibitor and CDK1 overexpression on radiosensitivity, apoptosis and cell cycle in CC cells. SiHa and Hela cells were transfected with si-SNHG12 and anti-miR-148a or CDK1 overexpression plasmid. a , b The survival fractions of SiHa and Hela cells were assessed by clonogenic assay. c , d Flow cytometry was used to determine the apoptosis of SiHa and Hela cells treated with 2 Gy radiation. e , f Caspase-3 Activity Assay Kit was used to detect the caspase-3 activity of SiHa and Hela cells treated with 2 Gy radiation. g , h The cell cycle distribution in SiHa and Hela cells treated with 2 Gy radiation was determined using flow cytometry. i , j The protein expression of CCND1 in SiHa and Hela cells treated with 2 Gy radiation was tested by WB analysis. * P < 0.05

Article Snippet: After blocking with non-fat milk for 2 h, the membranes were incubated with primary antibodies CDK1 (1:500, BA0027-2, Boster, Wuhan, China), CCND1 (1:2000, PB0403, Boster), γ-H2AX (1:1000, AF5836, Beyotime) and β-actin (1:5000, BA2305, Boster) overnight at 4 °C, followed by incubating with secondary antibody (1:10,000, BA1056, Boster) for 1 h. Immunoreactive bands were visualized using enhanced chemiluminescence reagent (Millipore).

Techniques: Over Expression, Transfection, Plasmid Preparation, Clonogenic Assay, Flow Cytometry, Caspase-3 Activity Assay, Activity Assay, Expressing

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Article Title: Magnolol alleviates hypoxia-induced pulmonary vascular remodeling through inhibition of phenotypic transformation in pulmonary arterial smooth muscle cells.

doi: 10.1016/j.biopha.2022.113060

Figure Lengend Snippet: Fig. 3. Effects of magnolol on the phenotypic transformation of pulmonary arteries in hypoxia-induced PH rats. (A) Representative images of immunohistochemistry staining for Ki67 (cell proliferation markers) in each group; (B-F) The protein expression of SM-22α, CyclinD1, OPN, and PCNA in the pulmonary artery of rats; Data are expressed as mean ± SD. +Mag(L): hypoxia+ magnolol (10 mg/kg/d); +Mag(H): hypoxia+ magnolol (20 mg/kg/d). **P < 0.01 vs Control; #P < 0.05, ##P < 0.01 vs Hypoxia.

Article Snippet: The PVDF membranes were blocked with 5% BSA and then incubated with the following primary antibodies: collagen I (No. ab34710, 1:1000, Abcam), collagen III (No. ab7778, 1:1000, Abcam), SM-22α (No. ab14106, 1:1000, Abcam), α-SMA (No. 19245, 1:1000, Cell Signaling Technology), OPN (No. ab91655, 1:1000, Abcam), PCNA (No. AF0261, 1:1000, Beyotime), calponin (No. AF1393, 1:1000, Beyotime), CyclinD1 (No. BM4272, 1:2000, BOSTER), p-JAK2 (No. ab32101, 1:1000, Abcam), JAK2 (No. AF1489, 1:2000, Beyotime), p-STAT3 (No. 13332, 1:1000, Signalway Antibody), STAT3 (No. 41465, 1:1000, Signalway Antibody), α-tubulin (No. sc-5286, 1:200, Santa Cruz) and β-actin (No. AF5001, 1:1000, Beyotime).

Techniques: Transformation Assay, Immunohistochemistry, Staining, Expressing, Control

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Article Title: Magnolol alleviates hypoxia-induced pulmonary vascular remodeling through inhibition of phenotypic transformation in pulmonary arterial smooth muscle cells.

doi: 10.1016/j.biopha.2022.113060

Figure Lengend Snippet: Fig. 5. Effects of magnolol on the proliferation, migration, and phenotypic transformation of PASMCs induced by hypoxia. (A) The cell viability was detected by the CCK-8 array. (B-C) Representative pictures of EdU staining. (D-E) The cell migration ability was detected by Transwell and scratch arrays. (F-G) The protein expression of SM-22α, α-SMA, Calponin, OPN, CyclinD1, PCNA, and collagen I in PASMCs. Data are expressed as mean ± SD. +Mag(L): hypoxia+ magnolol (10 mg/ kg/d); +Mag(H): hypoxia+ magnolol (20 mg/kg/d). **P < 0.01 vs Control; #P < 0.05, ##P < 0.01 vs Hypoxia.

Article Snippet: The PVDF membranes were blocked with 5% BSA and then incubated with the following primary antibodies: collagen I (No. ab34710, 1:1000, Abcam), collagen III (No. ab7778, 1:1000, Abcam), SM-22α (No. ab14106, 1:1000, Abcam), α-SMA (No. 19245, 1:1000, Cell Signaling Technology), OPN (No. ab91655, 1:1000, Abcam), PCNA (No. AF0261, 1:1000, Beyotime), calponin (No. AF1393, 1:1000, Beyotime), CyclinD1 (No. BM4272, 1:2000, BOSTER), p-JAK2 (No. ab32101, 1:1000, Abcam), JAK2 (No. AF1489, 1:2000, Beyotime), p-STAT3 (No. 13332, 1:1000, Signalway Antibody), STAT3 (No. 41465, 1:1000, Signalway Antibody), α-tubulin (No. sc-5286, 1:200, Santa Cruz) and β-actin (No. AF5001, 1:1000, Beyotime).

Techniques: Migration, Transformation Assay, CCK-8 Assay, Staining, Expressing, Control